Results 261 to 270 of about 198,039 (308)

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

The cost-effectiveness analysis of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient advanced colorectal cancer. [PDF]

Sci Rep
Yang P, Pei Z, Zhou Y, Pei H.
europepmc   +1 more source

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.
What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. [PDF]

Oncologist
LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K.   +7 more
europepmc   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota, Takeo Kosaka, Tatsuaki Daimon, Shinnosuke Fujiwara, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya   +6 more
wiley   +1 more source

A Retrospective Study of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer in the Elderly. [PDF]

Aging Med (Milton)
Yang S, Zhu Y, Liu S, Xiao K.
europepmc   +1 more source

Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns

The Prostate, Volume 86, Issue 4, Page 440-450, March 2026.
ABSTRACT Purpose Genetic testing is recommended but underutilized in advanced prostate cancer. Given known disparities affecting Black patients, we assessed genetic testing completion rates by race. Methods Henry Ford Health's electronic medical record was queried for new prostate cancer diagnoses (1/1/2017–6/30/2022).
Kyle C. McElyea, James P. Purtell, Avery K. Supernois, Courtney M. Rose, Farhan Ibrahim, Mohammed A. Baseer, Sunita Ghosh, Clara Hwang   +7 more
wiley   +1 more source

Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]

PLoS One
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc   +1 more source

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 515-524, February 2026.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management. [PDF]

Cureus
SirDeshpande P, Hegde SBS, Akhtar H.
europepmc   +1 more source